Iconovo AB

Iconovo prepares to celebrate the 10-Year anniversary today. We greet our guests welcome. Breathtaking innovation.

Iconovo is raising new capital to support its exciting projects in the field of inhalation. BIOSTOCK interviewed Johan Wäborg, CEO at Iconovo, with the introductory text: "An intranasal obesity treatment under development, a generic challenger to the asthma product Symbicort and discussions with potential partners are on the agenda for Iconovo". Read the full article at BIOSTOCK homepage (in Swedish only) https://lnkd.in/dVhHsvBd

Iconovo is proud to announce that the company's development partner Amneal Pharmaceuticals has completed a clinical pharmacokinetic pilot study comparing ICOres budesonide/formoterol and Symbicort Turbuhaler. The results from the study indicate that ICOres budesonide/formoterol will meet the criteria for demonstrating bioequivalence in an appropriately designed and powered study. The study represents an important step ahead of the initiation of a registration study of the product and Iconovo will proceed according to plan. https://lnkd.in/dJrWse-7

Iconovo receives positive guidance from FDA regarding substitutability for ICOpre Iconovo announces that the US Food and Drug Administration (FDA) has issued a positive guidance regarding the generic substitutability of the company's proprietary inhaler ICOpre® with the original drug Breo Ellipta with respect to external design and operating principles. The FDA's preliminary view is that ICOpre with its current external design attributes and operating principle is appropriate for submission in an Abbreviated New Drug Application (ANDA) for a generic Breo product. In addition, the FDA provides guidance regarding the configuration of the final ANDA to be able to provide substitutability. NB: Image below is not the latest design of ICOpre. To read the full press release, please follow link below. https://lnkd.in/dhPTkS7e

The Nordic Life Science Days in Malmö has started. Hope to see you and talk more about Dry Powder Inhalation!

Biostock news this morning: The future of obesity treatment: Iconovo develops intranasal semaglutide Biostock has released an article laying out Iconovo's plan to develop intranasal semaglutide in ICOone Nasal for the treatment of obesity. Iconovo has already pursued similar reformulations with other customer's API, now we will push this project to preclinical PoC and look for partner for the clinical development. Read the full article by following the link: https://lnkd.in/dJ6Y4FC4..

Second day at the ”Exploring the Future of Inhalation Drug Delivery” conference in Parma. A fantastic scientific program with great speakers and topics. The future of inhaled biologics looks bright and Iconovo is a part of it.

Iconovo develops intranasally inhaled semaglutide in ICOone Nasal for more user-friendly treatment of overweight and obesity Iconovo announces that the company has initiated the development of the GLP-1 analogue semaglutide in the inhaler ICOone Nasal for intranasal treatment of overweight and obesity. The initiative is based on in-depth analyses of the commercial opportunities for more user-friendly forms of administration of GLP-1. To read the full press release: https://lnkd.in/dt_559Qw